LiJ, HeY, RenB, et al.The thyroid condition and residual clinical signs in 31 existing endemic neurological cretins after 42 years of iodine supplementation in China. Front Endocrinol (Lausanne), 2022; 13:911487; doi: 10.3389/fendo.2022.911487
2.
YangY, GuoT, FuJ, et al.Association of preconception thyrotropin levels with fecundability and risk of spontaneous abortion in China. JAMA Netw Open, 2022; 5(8):e2228892; doi: 10.1001/jamanetworkopen.2022.28892
3.
AlexanderEK.Moving from the present to the future-elucidating the association of thyroid dysfunction with pregnancy outcomes. JAMA Netw Open, 2022; 5(8):e2231009; doi: 10.1001/jamanetworkopen.2022.31009
4.
OsingaJAJ, DerakhshanA, PalomakiGE, et al.TSH and FT4 reference intervals in pregnancy: A systematic review and individual participant data meta-analysis. J Clin Endocrinol Metab, 2022; 107(10):2925–2933; doi: 10.1210/clinem/dgac425
5.
OzardaY, SikarisK, StreichertT, et al.Distinguishing reference intervals and clinical decision limits—A review by the IFCC Committee on Reference Intervals and Decision Limits. Crit Rev Clin Lab Sci, 2018; 55(6):420–431; doi: 10.1080/10408363.2018.1482256
6.
EttlesonMD, RaineA, BatistuzzoA, et al.Brain fog in hypothyroidism: Understanding the patient's perspective. Endocr Pract, 2022; 28(3):257–264; doi: 10.1016/j.eprac.2021.12.003
7.
BritoJP, DengY, RossJS, et al.Association between generic-to-generic levothyroxine switching and thyrotropin levels among US adults. JAMA Intern Med, 2022; 182(4):418–425; doi: 10.1001/jamainternmed.2022.0045
8.
JonklaasJ, BiancoAC, BauerAJ, et al.Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid, 2014; 24(12):1670–1751; doi: 10.1089/thy.2014.0028
9.
JonklaasJ, BiancoAC, CappolaAR, et al.Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: A consensus document. Thyroid, 2021; 31(2):156–182; doi: 10.1089/thy.2020.0720
10.
DumitrescuAM, HanlonEC, ArosemenaM, et al.Extended absorption of liothyronine from poly-zinc-liothyronine: results from a phase 1, double-blind, randomized, and controlled study in humans. Thyroid, 2022; 32(2):196–205; doi: 10.1089/thy.2021.0304
11.
EvronJM, HummelSL, Reyes-GastelumD, et al.Association of thyroid hormone treatment intensity with cardiovascular mortality among US veterans. JAMA Netw Open, 2022; 5(5):e2211863; doi: 10.1001/jamanetworkopen.2022.11863
12.
CheeYJ, LiewH, HoiWH, et al.SARS-CoV-2 mRNA vaccination and graves' disease: A report of 12 cases and review of the literature. J Clin Endocrinol Metab, 2022; 107(6):e2324–e2330; doi: 10.1210/clinem/dgac119
13.
WongCKH, LuiDTW, XiongX, et al.Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: A population-based study of 2.3 million vaccine recipients. BMC Med, 2022; 20(1):339; doi: 10.1186/s12916-022-02548-1
14.
DouglasRS, KahalyGJ, PatelA, et al.Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med, 2020; 382(4):341–352; doi: 10.1056/NEJMoa1910434
15.
DouglasRS, KahalyGJ, UgradarS, et al.Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology, 2022; 129(4):438–449; doi: 10.1016/j.ophtha.2021.10.017
16.
McLeodDSA, BednoSA, CooperDS, et al.Pre-existing thyroid autoimmunity and risk of papillary thyroid cancer: A nested case-control study of US active-duty personnel. J Clin Oncol, 2022; 40(23):2578–2587; doi: 10.1200/JCO.21.02618
17.
MortonLM, KaryadiDM, StewartC, et al.Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science, 2021; 372(6543); doi: 10.1126/science.abg2538
18.
FrancoAT, Ricarte-FilhoJC, LaetschTW, et al.Oncogene-specific inhibition in the treatment of advanced pediatric thyroid cancer. J Clin Invest, 2021; 131(18):e152696; doi: 10.1172/JCI152696
19.
LeeYA, LeeH, ImSW, et al.NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest, 2021; 131(18):e144847; doi: 10.1172/JCI144847
20.
RobenshtokE, NeemanB, RechesL, et al.Adverse histological features of differentiated thyroid cancer are commonly found in autopsy studies: Implications for treatment guidelines. Thyroid, 2022; 32(1):37–45; doi: 10.1089/thy.2021.0268
21.
ChouR, DanaT, HaymartM, et al.Active surveillance versus thyroid surgery for differentiated thyroid cancer: A systematic review. Thyroid, 2022; 32(4):351–367; doi: 10.1089/thy.2021.0539
22.
ChouR, DanaT, BrentGA, et al.Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: A systematic review. Thyroid, 2022; 32(6):613–639; doi: 10.1089/thy.2021.0666
23.
OrloffLA, NoelJE, StackBCJr, et al.Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck, 2022; 44(3):633–660; doi: 10.1002/hed.26960
24.
ShahA, MarakaS.Hypothyroid patients describe what brain fog feels like. Clin Thyroidol, 2022; 34:106–108.
25.
McAninchEA.Switching generic-to-generic levothyroxine does not change serum TSH. Clin Thyroidol, 2022; 34:295–297.
26.
McAninchEA.Phase 1 clinical trial of poly-sinc-liothyronine demonstrates slow-release serum T3 kinetics. Clin Thyroidol, 2022; 34:9–12.
27.
MarakaS.Overtreatment and undertreatment with thyroid hormone is associated with cardiovascular mortality. Clin Thyroidol, 2022 (in press).
28.
UdyavarNR, Morris-WisemanLF. Preexisting thyroid autoimmunity is associated with increased thyroid cancer risk. Clin Thyroidol, 2022; 34:250–252.
29.
Klubo-GwiezdzinskaJ.Childhood exposure to excess ionizing radiation is associated with dose-dependent fusions as molecular drivers of papillary thyroid cancer. Clin Thyroidol, 2022; 34:161–164.
30.
FrancisG.The future of molecular profiling for the treatment of pediatric thyroid cancer. Clin Thyroidol, 2022; 34:157–160.
31.
BalcerekMI, McLeodDSA. Prevalence of “higher-risk” adverse histological features found at autopsy in patients with occult differentiated thyroid cancer. Clin Thyroidol, 2022; 34:127–131.
32.
BiondiB.A systematic review on the benefits and harms of active surveillance versus immediate surgery for low-risk differentiated thyroid cancer. Clin Thyroidol, 2022; 34:169–173.
33.
Solis-PazminoP, BritoJP. Is thyroglobulin a useful marker in the monitoring of differentiated thyroid cancer following lobectomy or without radioactive iodine?. Clin Thyroidol, 2022; 34:355–357.
